证券简称：健麾信息 证券代码：605186 公告编号：2023-027 上海健麾信息技术股份有限公司 关于与专业投资机构合作暨投资基金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带 责任。 重要内容提示： 基金名称： 深圳市弘盛健麾医疗产业创业投资基金合伙企业（有限合伙 ）(以下简称"本基金") 投资金额：上海健麾信息技术股份有限公司（以下简称"公司"）作为有 限合伙人认缴出资额2800万元人名币。 本次交易不构成关联交易或同业竞争，不构成重大资产重组；本次交易 无需提交董事会或股东大会审议。 风险提示： （一）由于私募股权基金投资具有周期较长、流动性较低等特点，公司本 次参与的投资基金的投资回报可能将面临较长的投资回收期。 （二）投资基金的投资回报受经济环境、行业周期、市场变化、监管政策 等诸多因素的影响，存在投资收益不及预期的风险。 一、本次投资概况 （一）本次投资基本情况 为进一步实现产业协同，借助专业机构的专业力量及资源优势，发掘并 投资医疗大健康产业领域的优质项目，推进产业与资本的有效融合。在不影 响公司日常 ...

根据《中华人民共和国公司法》《中华人民共和国证券法》《证券发行上市保 荐业务管理办法》《上海证券交易所股票上市规则》《上海证券交易所上市公司自 律监管指引第 11 号——持续督导》等有关规定，国信证券股份有限公司（简称 "国信证券"或"保荐机构"）负责上海健麾信息技术股份有限公司（简称"健 麾信息"、"上市公司"或"公司"）首次公开发行股票上市后的持续督导工作， 对健麾信息首次公开发行股票部分限售股持有人持有的限售股将上市流通情况 进行了审慎核查，现将核查情况及核查意见发表如下： 一、本次解除限售前公司限售股份概况 2020 年 11 月 27 日，经中国证券监督管理委员会《关于核准上海健麾信息 技术股份有限公司首次公开发行股票的批复》（证监许可[2020]3211 号）核准， 上海健麾信息技术股份有限公司（以下简称"公司"或"健麾信息"）向社会公 众首次公开发行人民币普通股（A 股）34,000,000 股，并于 2020 年 12 月 22 日 在上海证券交易所挂牌上市。公司首次公开发行前总股本为 102,000,000 股，首 次公开发行后总股本为 136,000,000 股，其中有限售条件流通股 10 ...

证券代码：605186 证券简称：健麾信息 公告编号：2023-026 上海健麾信息技术股份有限公司 首次公开发行限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 如有董事对临时公告内容的真实性、准确性和完整性无法保证或存在异议 的，公司应当在公告中作特别提示。 重要内容提示： 本次股票上市类型为首发股份；股票认购方式为网下，上市股数 为 69,368,222 股。 本次股票上市流通总数为 69,368,222 股。 本次股票上市流通日期为 2023 年 12 月 22 日。 一、本次限售股上市类型 2020 年 11 月 27 日，经中国证券监督管理委员会《关于核准上海健麾信 息技术股份有限公司首次公开发行股票的批复》（证监许可[2020]3211 号）核准， 上海健麾信息技术股份有限公司（以下简称"公司"或"健麾信息"）向社会公 众首次公开发行人民币普通股（A 股）34,000,000 股，并于 2020 年 12 月 22 日在上海证券交易所挂牌上市。公司首次公开发行前总股本为 102,000,00 ...

Financial Performance - The company's operating revenue for Q3 2023 was ¥64,356,620.87, a decrease of 43.28% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥18,234,704.78, down 41.74% year-on-year[6]. - The net profit excluding non-recurring gains and losses was ¥6,127,927.80, reflecting a significant decline of 78.54% compared to the previous year[6]. - Basic earnings per share for the period were ¥0.13, a decrease of 43.48% from the same quarter last year[6]. - Total operating revenue for the first three quarters of 2023 was ¥241,228,692.12, a decrease of 12.4% compared to ¥275,357,637.72 in the same period of 2022[22]. - Net profit for the first three quarters of 2023 was ¥74,485,546.03, down 13.4% from ¥85,932,346.82 in the previous year[24]. - Earnings per share (EPS) for the first three quarters was ¥0.54, compared to ¥0.63 in the same period last year[24]. - The company reported a profit before tax of ¥83,629,513.60, down from ¥98,880,594.21, a decrease of 15.4%[23]. Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥1,300,279,180.23, representing an increase of 8.46% compared to the end of the previous year[6]. - Total assets as of September 30, 2023, reached ¥1,300,279,180.23, up from ¥1,198,844,121.40, indicating an increase of approximately 8.5%[18]. - Non-current assets totaled ¥484,577,931.82, compared to ¥368,877,757.89, marking a significant increase of around 31.3%[18]. - The total liabilities increased to ¥150,033,361.33, compared to ¥115,583,848.53 in the previous year, reflecting a growth of 29.8%[22]. - The total liabilities include accounts payable of ¥35,204,006.22, which increased from ¥24,304,484.12, a rise of approximately 44.8%[18]. - Short-term borrowings amounted to ¥50,000,000.00, indicating the company is leveraging debt[18]. Cash Flow - Cash flow from operating activities showed a net outflow of ¥60,962,902.96 for the year-to-date, a decline of 919.04%[6]. - The net cash flow from operating activities for Q3 2023 was -60,962,902.96, a significant decline compared to 7,443,226.91 in Q3 2022, indicating a negative cash flow trend[28]. - Total cash inflow from financing activities was 50,590,000.00, while cash outflow was 12,055,288.95, resulting in a net cash flow of 38,534,711.05, contrasting with a negative net cash flow of -11,724,045.49 in the same quarter last year[29]. - The total cash and cash equivalents at the end of Q3 2023 stood at 231,996,500.60, down from 387,434,583.17 at the end of Q3 2022, reflecting a decrease of approximately 40% year-over-year[29]. - Cash inflow from investment activities was 24,919,368.46, while cash outflow was 104,610,062.80, leading to a net cash flow of -79,690,694.34, which is a slight increase in negative cash flow compared to -76,612,643.19 in Q3 2022[28]. - Operating cash inflows totaled 221,343,371.29, down from 249,687,999.98 in the previous year, representing a decrease of about 11.3%[28]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 9,032[14]. - The largest shareholder, Dai Jianwei, holds 57,113,219 shares, representing 42.0% of the total shares[14]. Inventory and Receivables - Accounts receivable increased to ¥363,971,553.84 from ¥332,887,498.88, reflecting a growth of about 9.4%[16]. - The company reported a significant increase in inventory, which rose to ¥89,952,757.14 from ¥74,023,447.28, reflecting a growth of about 21.5%[16]. - Other receivables increased to ¥28,512,117.12 from ¥10,828,485.10, showing a substantial increase of approximately 163.5%[16]. Future Plans - The company attributed the revenue decline to delayed customer purchases and limited business channel expansion, with last year's high base effect due to the post-pandemic recovery in Shanghai[11]. - The company plans to focus on new product development and market expansion strategies in the upcoming quarters[20]. - The company plans to continue focusing on investment activities despite the negative cash flow, indicating a strategic approach to future growth and market expansion[28]. Audit and Compliance - The company did not conduct an audit for the Q3 financial report, and there were no non-standard opinions from auditors[4].

一、募集资金基本情况 根据中国证券监督管理委员会(以下简称"中国证监会")出具的《关于核 准上海健磨信息技术股份有限公司首次公开发行股票的批复》(证监许可 [2020]3211 号 ),公司于2020年12月首次公开发行人民币普通股(A股)34,000,000 股。公司每股发行价格为人民币 14.20 元,本次募集资金总额为人民币 482,800,000.00 元，扣除各项发行费用（不含增值税）人民币 47,588,127.72 元, 实际募集资金净额为人民币 435,211,872.28 元。上述募集资金到位情况已经立信 会计师事务所（特殊普通合伙）于 2020年 12 月 17 日出具的信会师报字[2020] 第 ZA16027 号《验资报告》审验确认。为规范募集资金管理和使用,公司已开 设了相关募集资金专项账户,对募集资金实施专户存储。募集资金到账后,已全 部存放于募集资金专户,并与保荐机构、募集资金专户监管银行签署了募集资金 三方监管协议。 根据公司《首次公开发行股票招股说明书》,本次发行后募集资金扣除发行 费用后,投入以下项目: 单位: 万元 国信证券股份有限公司 关于上海健磨信息技术股份有限公司 ...

证券代码：605186 证券简称： 健麾信息 公告编号：2023-023 上海健麾信息技术股份有限公司 第二届董事会第十八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 上海健麾信息技术股份有限公司（以下简称"公司"）第二届董事会第十八 次会议于 2023 年 10 月 27 日上午以现场结合通讯方式召开，会议通知及相关材 料已于 2023 年 10 月 20 日通过电子邮件方式送达各位董事。本次会议应出席董 事 8 人，实际出席董事 8 人，全体董事均亲自出席了本次会议。本次会议由公司 董事长戴建伟先生主持，公司全体监事和高级管理人员列席。 本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法律法 规和《公司章程》等有关规定。 二、董事会会议审议情况 经与会董事认真审议，会议形成了以下决议： 1、审议通过《关于<2023 年第三季度报告>的议案》 根据《中华人民共和国证券法》、《上海证券交易所股票上市规则》、《上海证 券交易所上市公司自律监管指南第 1 号-公告格式》等规定， ...

证券代码：605186 证券简称： 健麾信息 公告编号：2023-025 上海健麾信息技术股份有限公司 关于使用部分闲置募集资金临时补充流动资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 上海健麾信息技术股份有限公司（以下简称"公司"）拟使用部分闲置募集 资金 1.2 亿元临时补充流动资金，使用期限自董事会审议通过之日起不超过 12 个月。 一、募集资金基本情况 （一）实际募集资金金额、资金到账情况 根据中国证券监督管理委员会（以下简称"中国证监会"）出具的《关于核 准上海健麾信息技术股份有限公司首次公开发行股票的批复》（证监许可 [2020]3211号），公司于2020年12月首次公开发行人民币普通股（A股）34,000,000 股。公司每股发行价格为人民币 14.20 元，本次募集资金总额为人民币 482,800,000.00 元，扣除各项发行费用（不含增值税）人民币 47,588,127.72 元， 实际募集资金净额为人民币 435,211,872.28 元。上述募集资金到位情况已经立信 会计 ...

证券代码：605186 证券简称： 健麾信息 公告编号：2023-024 上海健麾信息技术股份有限公司 第二届监事会第十五次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 上海健麾信息技术股份有限公司（以下简称"公司"）第二届监事会第十五 次会议于 2023 年 10 月 27 日上午以现场结合通讯方式召开，会议通知及相关材 料已于 2023 年 10 月 20 日通过电子邮件方式送达各位监事。本次会议应出席监 事 3 人，实际出席监事 3 人，全体监事均亲自出席了本次会议。本次会议由公司 监事会主席刘羽洋先生主持。 本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法律法 规和《公司章程》等有关规定。 二、监事会会议审议情况 经与会监事认真审议，会议形成了以下决议： 1、 审议通过《关于<2023 年第三季度报告>的议案》 上海健麾信息技术股份有限公司监事会 2023 年 10 月 31 日 监事会认为：公司 2023 年第三季度报告的编制和审核程序符合法律、行政法规 及中国证 ...

证券代码：605186 证券简称：健麾信息 公告编号：2023-022 上海健麾信息技术股份有限公司 关于参与投资私募基金的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、事项概述 上海健麾信息技术股份有限公司（以下简称"公司"）与上海弘盛君浩股权 投资基金管理有限公司（以下简称"弘盛君浩"）、海南弘盛厚泽投资合伙企业 （有限合伙）（以下简称"弘盛厚泽"）及其他合伙人共同出资发起设立上海弘 盛厚德私募股权投资基金合伙企业（有限合伙）（以下简称"弘盛厚德"，弘盛 厚德已在中国证券投资基金业协会完成备案手续并取得《私募投资基金备案证 明》，具体内容详见公司于2023年3月11日、2023年04月19日在上海证券交易所 网站 （www.sse.com.cn）披露的《关于参与投资私募基金的公告》、《关于参与 投资私募基金的进展公告》（公告编号：2023-001、2023-003）。 二、进展情况 近日，公司收到基金管理人弘盛君浩的通知，经全体合伙人协商一致，拟新 增有限合伙人杭州泰鲲股权投资基金合伙企业（有限合伙）（以下 ...

Financial Performance - The company's operating revenue for the first half of 2023 was CNY 176,872,071.25, representing a 9.26% increase compared to CNY 161,885,617.06 in the same period last year[24]. - The net profit attributable to shareholders of the listed company was CNY 55,812,371.66, a 2.67% increase from CNY 54,360,227.05 in the previous year[24]. - Basic earnings per share for the first half of 2023 were CNY 0.41, up 2.50% from CNY 0.40 in the same period last year[25]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 3.23% year-on-year[26]. - The company achieved operating revenue of CNY 176.87 million in the first half of 2023, a year-on-year increase of 9.26%[54]. - The net profit attributable to shareholders was CNY 55.81 million, reflecting a growth of 2.67% compared to the same period last year[54]. - The company reported a total profit for the first half of 2023 was ¥62,846,060.34, a slight decrease from ¥63,100,581.37 in the same period of 2022[150]. - The company’s total comprehensive income for the first half of 2023 was ¥56,421,052.94, compared to ¥54,537,377.95 in the first half of 2022[151]. Cash Flow and Liquidity - The net cash flow from operating activities was negative CNY 71,395,692.74, a significant decrease of 859.86% compared to a positive cash flow of CNY 9,395,849.83 in the same period last year[24]. - Operating cash flow showed a significant decline, with a net outflow of CNY 71.40 million, compared to a net inflow of CNY 9.40 million in the previous year[62]. - Total cash inflow from operating activities decreased to 127,141,917.65 RMB in H1 2023, down 29.5% from 180,429,676.75 RMB in H1 2022[156]. - Cash outflow from operating activities increased to 198,537,610.39 RMB in H1 2023, compared to 171,033,826.92 RMB in H1 2022, reflecting a rise of 16.1%[156]. - The company reported a significant increase in cash and cash equivalents at the end of H1 2023, totaling 224,495,448.66 RMB, down from 414,146,712.82 RMB at the end of H1 2022[157]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,242,440,463.80, reflecting a 3.64% increase from CNY 1,198,844,121.40 at the end of the previous year[24]. - Current liabilities decreased to CNY 100,144,137.98 from CNY 113,243,848.53, a reduction of about 11.5%[143]. - Total liabilities increased to CNY 102,419,137.98 from CNY 115,583,848.53, a decrease of about 11.4%[144]. - The company's total current assets amounted to RMB 804,145,980.53, a decrease from RMB 829,966,363.51 at the end of 2022, reflecting a decline of approximately 3.9%[142]. - The company's cash and cash equivalents were reported at RMB 257,524,911.67, down from RMB 366,273,999.90, indicating a decrease of about 29.8%[142]. Investments and Subsidiaries - The company has invested ¥30 million in the Shanghai Hongsheng Houde Private Equity Investment Fund, representing an 8.1079% stake, focusing on the healthcare sector[72]. - The company is actively optimizing the equity structure of its subsidiaries and expanding its investment in the healthcare industry through private equity funds[69]. - The company’s subsidiary, Wei Le Hai Ci, reported total assets of €30,551.50 million and a net profit of €306.94 million[74]. - The subsidiary, Shan Tao Information, had total assets of ¥28,283.34 million and a net profit of ¥2,135.49 million[74]. - The company completed the transfer of 100% equity of Boke Medical for 5.33 million RMB, which is no longer included in the consolidated financial statements[84]. Market Position and Strategy - The company is positioned to benefit from the increasing demand for intelligent pharmaceutical management systems as traditional methods become insufficient[33]. - The company aims to expand its market presence by exploring overseas markets and replicating successful business models like the "Zhongxiang model"[53]. - The company signed a joint venture agreement with Ajlan & Bros Information Technology Company to establish a new company in Riyadh, Saudi Arabia, aiming to expand into the Middle East and North Africa markets[55]. - The company is actively promoting the "Zhongxiang Model" for replicable "to-G" business, enhancing cooperation with local governments to develop healthcare projects[56]. - The company has established a strategic partnership to enhance its product line and expand its market presence in the healthcare sector[69]. Research and Development - Research and development expenses increased by 5.49% to CNY 10.95 million, reflecting the company's commitment to new product development[62]. - The company is currently developing new products such as hospital logistics robots and automated drug dispensing machines to enhance service offerings[42]. - The company has established a comprehensive R&D system with nearly 20 years of experience in intelligent drug management, ensuring strong innovation capabilities[46]. Risks and Challenges - The company has highlighted potential risks in its operations, urging investors to pay attention to these risks[7]. - The industry is in a recovery phase post-pandemic, with clients in the hospital and pharmaceutical distribution sectors facing financial constraints[26]. - The company has faced challenges such as economic pressures and regulatory actions in the pharmaceutical sector but continues to strengthen its market position[53]. Shareholder Commitments and Governance - The company has a long-term commitment from major shareholders to ensure stability in shareholding structure[94]. - The company will not repurchase shares during the lock-up period and will ensure compliance with all relevant laws and regulations regarding share transfers[99]. - The company commits that the prospectus does not contain false records, misleading statements, or major omissions, and assumes legal responsibility for its authenticity, accuracy, and completeness[112]. - The controlling shareholders commit to avoid any competition with the company and will not engage in similar business activities that could harm the company's interests[115]. - Major shareholders are also bound to fulfill their commitments and must extend their lock-up period until all negative impacts from any non-fulfillment are resolved[108].